Certificate of Analysis (CoA) is an official document issued by the manufacturer of the medicinal product. It contains information on some critical quality characteristics of the medicine. Click here to learn more. CoA’s are available only for some medicines and limited batches. Customers can order the medicinal product CoA together with the aliquots of the same batch.
Certificate of Analysis(from reference drug manufacturer) | Batch Number | Expiry Date | Price | |
|---|---|---|---|---|
|
CoA – Avastin | Bevacizumab | VEGF-A | B8800H28 |
B8800H28 |
03/2021 |
150,00 € |
|
|
CoA – Humira | Adalimumab | TNF-α | 02006LX02 |
02006LX02 |
01/2021 |
150,00 € |
|
|
CoA – Humira | Adalimumab | TNF-α | 040309A07 |
040309A07 |
03/2021 |
150,00 € |
|
|
CoA – Humira | Adalimumab | TNF-α | 70225XH07 |
70225XH07 |
09/2018 |
150,00 € |
|
|
CoA – Humira | Adalimumab | TNF-α | 73254XH03 |
73254XH03 |
12/2018 |
150,00 € |
|
|
CoA – Humira | Adalimumab | TNF-α | 76287XH07 |
76287XH07 |
03/2019 |
150,00 € |
|
|
CoA – Humira | Adalimumab | TNF-α | 76287XH11 |
76287XH11 |
03/2019 |
150,00 € |
|
|
CoA – Humira | Adalimumab | TNF-α | 80315XH04 |
80315XH04 |
07/2019 |
150,00 € |
|
|
CoA – Humira | Adalimumab | TNF-α | 85364XH07 |
85364XH07 |
12/2019 |
150,00 € |
|
|
CoA – Humira | Adalimumab | TNF-α | 88400XH01 |
88400XH01 |
03/2020 |
150,00 € |
|
|
CoA – Perjeta | Pertuzumab | HER2 | H0332H02 |
H0332H02 |
11/2020 |
150,00 € |
|
|
CoA – Skyrizi | Risankizumab | IL23 | 1124728 |
1124728 |
06/2021 |
150,00 € |
|
|
CoA – Stelara | Ustekinumab | IL-12 | JKS2Gxx |
inquire for details |
10/2022 |
150,00 € |
|
|
CoA – Stelara | Ustekinumab | IL-12 | JKS2Gxy |
inquire for details |
10/2022 |
150,00 € |
|
|
CoA – Stelara | Ustekinumab | IL-12 | KCS11xx |
inquire for details |
02/2023 |
150,00 € |
|
|
CoA – Synagis | Palivizumab | RSV protein F | 382291 |
382291 |
04/2019 |
150,00 € |
|
|
CoA – Synagis | Palivizumab | RSV protein F | 382445 |
382445 |
06/2019 |
150,00 € |
|
|
CoA – Synagis | Palivizumab | RSV protein F | 382615 |
382615 |
10/2019 |
150,00 € |
|
|
CoA – Synagis | Palivizumab | RSV protein F | 382683 |
382683 |
02/2020 |
150,00 € |
|
|
CoA – Synagis | Palivizumab | RSV protein F | 382835 |
382835 |
08/2020 |
150,00 € |
|
|
CoA – Tecentriq | Atezolizumab | PD-L1 | B0006B01 |
B0006B01 |
03/2022 |
150,00 € |
|
|
CoA – Yervoy | Ipilimumab | CD152 / CTLA4 | ABE0468 |
ABE0468 |
08/2021 |
150,00 € |